Alyeska discloses 9.9% IN8bio (INAB) ownership in Schedule 13G

Rhea-AI Filing Summary

IN8bio, Inc. received a Schedule 13G showing that Alyeska Investment Group, Alyeska Fund GP, and Anand Parekh beneficially own 966,381 shares of common stock, representing 9.9% of the class as of December 31, 2025. The group reports no sole voting or dispositive power, but shared power over all reported shares.

The filing explains that Alyeska-related entities hold common stock, PIPE shares, and warrants, but the warrants are subject to a 9.9% ownership cap. Based on 9,761,425 IN8bio shares outstanding, the reporting persons certify the holdings were acquired in the ordinary course and not to influence control.

Insights

Equity ownership & governance analyst

Alyeska reports a capped 9.9% economic stake in IN8bio.

The filing shows Alyeska Investment Group, its general partner, and Anand Parekh collectively beneficially own 966,381 IN8bio common shares, or 9.9% of the class as of December 31, 2025. All voting and dispositive authority over these shares is shared, with no sole control reported.

Exhibit details show additional holdings via PIPE shares, pre-funded warrants, and other warrants, all constrained by a 9.9% ownership limitation. The percentage is calculated using 9,761,425 shares outstanding, combining amounts from a Form 10-Q and a Form 8-K. The signatories certify the position is held in the ordinary course and not for changing control, so this looks like a sizeable but passive institutional stake rather than an activist position.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

IN8bio, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

45674E208

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 45674E208

1

Names of Reporting Persons

Alyeska Investment Group, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 966,381.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 966,381.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

966,381.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 45674E208

1

Names of Reporting Persons

Alyeska Fund GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 966,381.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 966,381.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

966,381.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 45674E208

1

Names of Reporting Persons

Anand Parekh

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 966,381.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 966,381.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

966,381.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IN8bio, Inc.
(b)	Address of issuer's principal executive offices: 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
Item 2.
(a)	Name of person filing: (i) Alyeska Investment Group, L.P. (ii) Alyeska Fund GP, LLC (iii) Anand Parekh
(b)	Address or principal business office or, if none, residence: (i) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (ii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (iii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601
(c)	Citizenship: (i) Alyeska Investment Group, L.P. - Delaware (ii) Alyeska Fund GP, LLC - Delaware (iii) Anand Parekh - United States of America
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 45674E208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 966,381
(b)	Percent of class: 9.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 966,381
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 966,381
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alyeska Investment Group, L.P.

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	02/17/2026

Alyeska Fund GP, LLC

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	02/17/2026

Anand Parekh

Signature:	Anand Parekh
Name/Title:	Anand Parekh | Self
Date:	02/17/2026

Exhibit Information

The reporting persons are the beneficial owners of 13,165 shares of common stock, 944,319 common PIPE shares of the Issuer, hold pre-funded warrants to purchase 2,748,188 shares of the Issuer's Class A common stock, and hold warrants to purchase 196,097 shares of the Issuer's Class A common stock, (the "Warrants"). However, per their terms, the Warrants can only be exercised into such number of shares that would constitute 9.9% of the total number of Common Stock of the Issuer outstanding immediately after giving effect to the issuance of Common Stock upon exercise of this Warrant by the Holder. Accordingly, as of December 31, 2025 the reporting persons may only exercise up to 8,897 Ordinary Shares under the Warrant Agreement, and as such, is reporting beneficial ownership of only such number of shares. The percentage calculation assumes that there are currently 9,761,425 outstanding shares of Ordinary Shares of the Issuer, based upon (a) 4,634,396 shares of Common Stock outstanding on November 3, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and (b) 5,127,029 shares of Common Stock issued by the Issuer in the Private Placement, as reported in the Issuer's Current Report on Form 8-K filed on December 19, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

FAQ

What stake in IN8bio (INAB) does Alyeska report on this Schedule 13G?

Alyeska and related reporting persons disclose beneficial ownership of 966,381 shares of IN8bio common stock, representing 9.9% of the outstanding class as of December 31, 2025, with shared voting and dispositive power over all reported shares.

Who are the reporting persons on the IN8bio (INAB) Schedule 13G?

The Schedule 13G lists three reporting persons: Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh. Each reports beneficial ownership of the same 966,381 IN8bio shares, with no sole voting or dispositive power, only shared authority.

How did the filing calculate Alyeska’s 9.9% ownership of IN8bio (INAB)?

The 9.9% ownership is based on 9,761,425 IN8bio shares outstanding. This combines 4,634,396 shares reported in a Form 10-Q and 5,127,029 shares issued in a private placement disclosed in a Form 8-K, forming the denominator for the percentage calculation.

What types of IN8bio (INAB) securities does Alyeska hold according to the exhibit?

The exhibit states the reporting persons hold 13,165 common shares, 944,319 common PIPE shares, pre-funded warrants for 2,748,188 shares, and warrants for 196,097 shares. Warrant exercises are limited by a 9.9% ownership cap when calculating beneficial ownership.

What is the 9.9% ownership cap mentioned for IN8bio (INAB) warrants?

The warrants can only be exercised into shares such that holders own no more than 9.9% of IN8bio’s common stock after exercise. As of December 31, 2025, this cap allows exercise of only 8,897 shares under the warrant agreement for beneficial ownership reporting.

Is Alyeska seeking control of IN8bio (INAB) based on this Schedule 13G?

The certification explicitly states the securities were acquired and are held in the ordinary course of business, and not for the purpose or effect of changing or influencing control of IN8bio. It characterizes the position as passive rather than a control-seeking investment.